Sinovac Biotech
SVA
SVA was delisted on the 22nd of February, 2019.
35 hedge funds and large institutions have $128M invested in Sinovac Biotech in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 6 closing their positions.
110% more capital inflows, than outflows
Capital inflows: $8.28M | Capital outflows: $3.94M
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
1.11% more ownership
Funds ownership: 30.69% → 31.8% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 37 → 35 (-2)
17% less call options, than puts
Call options by funds: $176K | Put options by funds: $212K
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GLG Partners
London,
United Kingdom
|
+$3.25M |
| 2 |
Renaissance Technologies
New York
|
+$2.43M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.23M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$402K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.41M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$742K |
| 3 |
Spark Investment Management
New York
|
-$174K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
-$174K |
| 5 |
Goldman Sachs
New York
|
-$79K |
SVA Hedge Fund Activity: Q3 2017 in Review
35 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech (SVA) for Q3 2017, worth a combined $128M — up 8.2% from $118M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SVA and 4 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was GLG Partners, adding an estimated $3.25M. The largest seller was Morgan Stanley, cutting an estimated $2.41M.
- 35 institutional investors held Sinovac Biotech (SVA) as of Q3 2017, down from 37 in Q2 2017.
- Funds reported $128M of Sinovac Biotech stock for Q3 2017, up 8.2% quarter-over-quarter.
- 4 funds opened new Sinovac Biotech positions in Q3 2017 and 6 closed out, a net change of -2 holders.
- The largest Sinovac Biotech buyer in Q3 2017 was GLG Partners, an estimated $3.25M added.
- The largest Sinovac Biotech seller in Q3 2017 was Morgan Stanley, an estimated $2.41M sold.
Based on aggregated 13F filings for Q3 2017.